Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
Journal of Neuro-Oncology|September 25, 2025
Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groupsPaolo Tini, Flavio Donnini, Francesco Marampon, et al.
Oncology Letters|March 22, 2016
Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysisLuigi Zugaro, Mario DI Staso, Giovanni Luca Gravina, et al.
BJR Case Reports|October 10, 2022
Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature reviewFrancesco Marampon, Alain J Gelibter, Pier Rodolfo Cicco, et al.
BMC Cancer|December 2, 2015
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer modelsGiovanni Luca Gravina, Andrea Mancini, Patrizia Sanita, et al.
International Journal of Oncology|December 3, 2011
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Ilaria Giusti, et al.
International Journal of Oncology|January 3, 2025
[Retracted] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Ilaria Giusti, et al.
International Journal of Molecular Sciences|March 14, 2026
Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment OutcomeMatteo Cassandri, Paola Pontecorvi, Fabrizio Cece, et al.
Oncology Reports|December 21, 2012
Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cellsGiovanni Luca Gravina, Guido Ranieri, Paola Muzi, et al.
Journal of Hematology & Oncology|January 7, 2017
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastomaGiovanni Luca Gravina, Andrea Mancini, Francesco Marampon, et al.
International Journal of Molecular Sciences|September 9, 2022
The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic SclerosisTania Colasanti, Katia Stefanantoni, Cristina Fantini, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Journal of Neuro-Oncology|September 25, 2025
Timing matters: overall treatment time, radiotherapy interruptions, and outcomes in glioblastomas-prognostic significance in different biological sub-groupsPaolo Tini, Flavio Donnini, Francesco Marampon, et al.
Oncology Letters|March 22, 2016
Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysisLuigi Zugaro, Mario DI Staso, Giovanni Luca Gravina, et al.
BJR Case Reports|October 10, 2022
Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature reviewFrancesco Marampon, Alain J Gelibter, Pier Rodolfo Cicco, et al.
BMC Cancer|December 2, 2015
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer modelsGiovanni Luca Gravina, Andrea Mancini, Patrizia Sanita, et al.
International Journal of Oncology|December 3, 2011
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Ilaria Giusti, et al.
International Journal of Oncology|January 3, 2025
[Retracted] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Ilaria Giusti, et al.
International Journal of Molecular Sciences|March 14, 2026
Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment OutcomeMatteo Cassandri, Paola Pontecorvi, Fabrizio Cece, et al.
Oncology Reports|December 21, 2012
Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cellsGiovanni Luca Gravina, Guido Ranieri, Paola Muzi, et al.
Journal of Hematology & Oncology|January 7, 2017
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastomaGiovanni Luca Gravina, Andrea Mancini, Francesco Marampon, et al.
International Journal of Molecular Sciences|September 9, 2022
The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic SclerosisTania Colasanti, Katia Stefanantoni, Cristina Fantini, et al.
Pageof 16